A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate
(AXERT®) 12.5 milligram tablets compared with placebo for the acute treatment of migraine
headache at the earliest onset of headache pain. Almotriptan malate (AXERT®) is approved for
the treatment of migraine headache, with or without aura, in adults. Patients in this study
will take either almotriptan or placebo oral tablets for 3 consecutive migraine headaches.